Barzolvolimab Misses Atopic Dermatitis Endpoints

Company Celldex Therapeutics Event Type Phase 2 results (previously missed 19 Nov event) Modality Anti-KIT monoclonal antibody Asset Barzolvolimab Target KIT (mast cell depletion) Disease Area Moderate-to-severe atopic dermatitis Summary Celldex reported November 19 that Phase 2 barzolvolimab did not significantly improve peak itch versus…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *